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intralobar lung sequester, as was confirmed with histologic
examination of the resected left lower lobe. In retrospect, the
benefit of preserving a small diseased segment of the lung
seemed minor compared with the risk of infection and reopera-
tion in case of necrosis. Therefore, we believe that resection of
the affected lung segment remains the safest treatment option
for symptomatic intralobar lung sequester.
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False-positive mediastinal lymph
node activity on positron emission
tomographic scan after adjuvant treatment
of gynecologic malignancies
Bryan A. Whitson, MD, Sara J. Runge, BS, Shawn S. Groth, MD,
and Michael A. Maddaus, MD, Minneapolis, Minn
After patients have undergone adjuvant treatment forgynecologic malignancies, newly positive mediastinallymph nodes (LNs) on integrated 18-fluorodeoxyglucose(FDG) positron emission tomography (PET) and
computed tomography (CT) images may suggest recurrent meta-
static disease. We present the cases of 2 patients who underwent
cytoreductive abdominal surgery and adjuvant chemoradiation for
gynecologic malignancies whose subsequent follow-up surveil-
lance FDG-PET/CT scan results revealed PET-positive mediasti-
nal LNs. Neither patient had any previous thoracic disease, and
prior FDG-PET results were negative.
Clinical Summary
Patient 1
A 57-year-old woman with stage IIIc endometrioid uterine adeno-
carcinoma underwent total abdominal hysterectomy, bilateral
salpingo-oophorectomy, pelvic LN dissection, cytologic washings,
and omentectomy. Final pathology demonstrated tumor invasion
into the myometrium, positive estrogen and progesterone receptors
on the tumor, and metastasis to 2 of 31 resected pelvic LNs. Three
cycles of systemic chemotherapy (docetaxel and carboplatin),
whole pelvic radiotherapy and brachytherapy, and 3 additional
cycles of chemotherapy (docetaxel and carboplatin) were given.
An integrated FDG-PET/CT scan obtained 6 months after com-
pleting adjuvant treatment revealed newly positive perihilar and
subcarinal LN, raising concerns of metastatic disease (Figure 1).
Her carbohydrate antigen (CA)-125 level was 13 mg/dL (normal
range, 0-30 mg/dL). Diagnostic mediastinoscopy (stations 3, 4R,
and 7) was performed; the LN biopsy results demonstrated ne-
crotic granulomas negative for fungi, mycobacteria, and malig-
nancy. A repeat FDG-PET/CT scan 6 months later demonstrated
resolution of all abnormal metabolic activity (Figure 1, C). Follow-
up CA-125 levels have remained normal. Two years after the
initial operation, she is alive without evidence of recurrent
disease.
Patient 2
A 61-year-old woman with stage Ic uterine carcinosarcoma under-
went total abdominal hysterectomy, bilateral salpingo-oophorectomy,
pelvic LN dissection, cytologic washings, and omentectomy. Final
pathology demonstrated myometrial and angiolymphatic invasion.
None of the pelvic LNs were positive (0/25) for malignancy. She
underwent 3 cycles of adjuvant chemotherapy (cisplatin and ifos-
famide), whole pelvic radiotherapy, and 3 additional cycles of
systemic chemotherapy (cisplatin and ifosfamide). An integrated
FDG-PET/CT scan obtained 4 months into her chemoradiation
treatment demonstrated newly positive perihilar and subcarinal
LNs, raising concerns of metastatic disease. Diagnostic mediasti-
noscopy (stations 4R and 7) was performed. The LN biopsy results
demonstrated normal LN with no pathologic disease and were
negative for fungi and mycobacteria. Follow-up FDG-PET/CT
imaging 9 months later demonstrated resolution of the abnormal
mediastinal metabolic activity. Her CA-125 level was 45 mg/dL at
the time of mediastinoscopy and 12 mg/dL at the time of repeat
imaging. Fourteen months after the initial operation, she is without
evidence of recurrent disease.
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Discussion
Because of the fusion images of newer integrated PET/CT ma-
chines, CT and PET scans are increasingly used to screen for
recurrent disease in patients with cancer, individually, serially, or
concomitantly. When FDG-PET is used for preoperative staging,
false-positive results can occur. In Cerfolio and colleagues’ study1
of 400 patients with non–small cell lung cancer (NSCLC), the
false-positive rate was as high as 76% for preoperative N2
disease. They found that PET-positive LNs at station 4R, 4L,
and 7 were most likely to be false-positives (as in our 2
patients). When FDG-PET scans are used as a postoperative
surveillance tool in patients with NSCLC, false-positives can
also occur, but at a much lower rate. According to another
study, FDG-PET scans, when used for recurrence surveillance
at a median of 19 months after primary therapy in patients with
NSCLC, had a sensitivity of 93% and a specificity of 89%, with
only 2.7% false-positives (2/73).2
In 2 studies of gynecologic malignancies (uterine and cervical
carcinomas), FDG-PET scans used for surveillance after treatment
had a sensitivity of 90% to 96% and a specificity of 70% to 78%.3,4
The false-positive rate ranged from 10.7% to 65% for thoracic LN
lesions. The true mediastinal or hilar LN recurrence rate was
26.5% to 46.2%. However, the false-positive rate for hilar and
mediastinal LNs was as high as 73.5%.4 Neither of these gyneco-
logic studies routinely used serial FDG-PET examinations.
To our knowledge, no other specific cases have been reported
of delayed metabolic activation of mediastinal LNs causing false-
positive images after treatment for gynecologic malignancies. Pos-
sible explanations for false-positive LNs include infection, benign
inflammatory processes, and residual inflammation from local
treatment effects.3-5 In our 2 patients, the mediastinal LNs were
negative for fungi, bacteria, and malignancy, none of which were
manifest in the radiation field after adjuvant therapy.
New FGD-PET–positive mediastinal LNs manifesting after
treatment of gynecologic malignancies raise concerns for meta-
static disease. Although false-positives can occur, tissue biopsies
must be obtained to definitively exclude metastatic disease.
The authors thank Mary Knatterud, PhD, for her editorial
assistance.
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Figure 1. Selected images from serial integrated FDG-PET/CT scans of patient 1. A, This image, obtained after the
gynecologic surgery, demonstrates a calcified right perihilar LN with a maximum standard uptake value (SUV) of
4.0, believed to be consistent with granulomatous changes. B, This image, obtained after the end of adjuvant
chemotherapy and radiation treatment (6 months after image A), demonstrates that the same right perihilar LN, still
the same size (12 mm), now has a maximum SUV of 4.6. A subcarinal LN demonstrates new metabolic activity, with
a maximum SUV of 5.2. A left perihilar LN has increased in size (26 mm) with new metabolic activity and a
maximum SUV of 5.1. C, This image, obtained 6 months after the image in (B), demonstrates no areas of abnormal
metabolic activity.
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